MNG296
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.533
- MYC_TARGETS_V1+0.428
- UNFOLDED_PROTEIN_RESPONSE+0.385
- MTORC1_SIGNALING+0.371
- E2F_TARGETS+0.341
- G2M_CHECKPOINT+0.335
- TGF_BETA_SIGNALING+0.329
- OXIDATIVE_PHOSPHORYLATION+0.293
- GLYCOLYSIS+0.283
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.274
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.197
- APICAL_SURFACE-0.150
- INTERFERON_GAMMA_RESPONSE-0.149
- HEME_METABOLISM-0.084
- KRAS_SIGNALING_DN-0.083
- BILE_ACID_METABOLISM-0.074
- COMPLEMENT-0.035
- FATTY_ACID_METABOLISM-0.035
- MYOGENESIS-0.001
- COAGULATION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.863 |
| 2 | BS_1D6PZNKN | Diffuse intrinsic pontine glioma | — | 0.853 |
| 3 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.848 |
| 4 | SRR12696801 | — | — | 0.847 |
| 5 | MNG544 | — | — | 0.844 |
| 6 | SRR12696793 | — | — | 0.842 |
| 7 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.833 |
| 8 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.833 |
| 9 | MNG252 | — | — | 0.822 |
| 10 | SRR12696771 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.533 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.428 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.385 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.371 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.341 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.335 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.329 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.293 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.283 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.274 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.227 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.208 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.205 | Remibrutinib | — uncovered |
| HYPOXIA | 0.205 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.198 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.179 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.154 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.154 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.151 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.143 | Idelalisib | — uncovered |